Company Filing History:
Years Active: 2014
Title: Mehdi Shahidi: Innovator in Cancer Treatment
Introduction
Mehdi Shahidi is a prominent inventor based in Sutton, GB. He has made significant contributions to the field of cancer treatment, particularly in addressing non-small cell lung cancer. His innovative approach has garnered attention in the medical community.
Latest Patents
Shahidi holds a patent for a method aimed at treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR). The patent, titled "Method for EGFR directed combination treatment of non-small cell lung cancer," describes a regimen involving an irreversible tyrosine kinase inhibitor (TKI) administered continuously at an average daily dose ranging from 10 to 50 mg. Additionally, a monoclonal antibody (mAB) is co-administered according to a dosing regimen that varies from an average weekly intravenous dose of 50 to 500 mg, repeated thrice, twice, or once a week, or at intervals of two to three weeks, or at least monthly.
Career Highlights
Shahidi is associated with Boehringer Ingelheim International GmbH, where he continues to work on innovative solutions in cancer treatment. His dedication to research and development has positioned him as a key figure in the pharmaceutical industry.
Collaborations
He collaborates with notable colleagues, including Louis Denis and Robert Michael Lorence, to advance research in cancer therapies. Their combined expertise contributes to the development of effective treatment options for patients.
Conclusion
Mehdi Shahidi's work in cancer treatment exemplifies the impact of innovation in medicine. His patent and ongoing research efforts highlight the importance of targeted therapies in improving patient outcomes.